For over two years, no gene-editing company dared to go public. Scribe Therapeutics just priced a $129 million IPO at the top of its range, with Sanofi buying in alongside public investors. The gene-editing IPO drought is officially over.
A $129 Million Bet That the Ice Has Thawed
For more than two years, no gene-editing company dared to go public. The biotech IPO market was frozen solid, and the riskiest modalities (think: permanently rewriting human DNA) were the last ones investors wanted to touch.
Then Scribe Therapeutics walked onto the Nasdaq this week and raised $129 million.
The Berkeley spinout priced 8.58 million shares at $15 apiece, landing at the top of its $13–$15 marketed range. That's Wall Street's way of saying "we actually want this." Scribe will trade under the ticker SCTX, and the offering is expected to close July 27.
This is the first IPO from a gene-editing company since Metagenomi raised about $94 million back in early 2024. Two years is an eternity in biotech time. So what changed?
The Company With a CRISPR Upgrade
Scribe isn't just another CRISPR shop. The company was founded in 2018, spun out of UC Berkeley's legendary gene-editing research ecosystem. Co-founder Benjamin Oakes serves as CEO, and Nobel laureate Jennifer Doudna is among the founding team.
But Scribe's pitch to investors isn't "we do CRISPR." It's "we built something better."
The company's technology starts with CasX, a lesser-known cousin of the Cas9 protein that most people associate with CRISPR. From CasX, Scribe engineered two platforms: XE (for traditional gene editing) and ELXR (for epigenetic silencing, which turns genes off without permanently cutting the DNA). Think of it like the difference between deleting a file from your computer and simply locking it so nobody can open it.
That distinction matters. Epigenetic silencing could be reversible in theory, which makes regulators a little less nervous about permanent, irreversible changes to a patient's genome.
Cholesterol: The Trillion-Dollar Target
Scribe's lead program, STX-1150, is aimed squarely at , a gene that acts like a volume knob for LDL cholesterol (the "bad" kind). Turn PCSK9 down, and LDL drops. It's one of the most genetically validated drug targets in existence: people born with naturally broken PCSK9 genes tend to have low cholesterol and fewer heart attacks.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
PCSK9
STX-1150 uses epigenetic silencing to suppress PCSK9 in the liver, delivered via tiny fat bubbles called lipid nanoparticles. The company planned to start first-in-human testing by mid-2026. Behind that lead program sit two preclinical assets: STX-1200 targeting Lp(a) (another cardiovascular risk factor) and STX-1400 targeting triglycerides.
If you're thinking "wait, there are already great cholesterol drugs," you're right. Repatha, Praluent, and Leqvio all go after PCSK9 through different mechanisms. They work well. But they require ongoing injections for life, and roughly half of patients quit their lipid-lowering therapy within a year. The dream here is a single treatment that lowers cholesterol permanently. One dose, decades of protection.
Scribe vs. the Gorilla in the Room
Scribe isn't alone in chasing that dream. Verve Therapeutics, now owned by Eli Lilly after a 2025 acquisition, is the clear front-runner in cardiovascular gene editing. Verve's PCSK9 program (VERVE-102) already has human data showing dose-dependent LDL reductions from a single dose, plus an FDA Fast Track designation.
Verve also has an ANGPTL3 program (VERVE-201) for the most severe cholesterol disorders and preclinical work on Lp(a). Lilly's backing gives Verve manufacturing muscle, regulatory experience, and a balance sheet that a freshly public startup simply can't match.
So why does Scribe think it can compete? The epigenetic angle is the key differentiator. Verve uses base editing, which makes small, permanent changes to DNA letters. Scribe's ELXR platform silences genes without cutting or rewriting them at all. For a field still grappling with questions about off-target edits and irreversibility, that could be a meaningful selling point with regulators and patients alike.
It's a bit like two restaurants on the same block. Both serve steak. But one grills it and the other sous-vides it, and the difference in technique might matter a lot to certain diners.
The IPO Window: Open, But Bring Your A-Game
Scribe's successful pricing is about more than one company. It's a signal flare for the entire gene-editing sector.
The biotech IPO market has been slowly defrosting. Only 11 biotech IPOs happened in all of 2025, a number analysts called "paltry." But 2026 has looked meaningfully better. Interest rates have moderated, and a backlog of companies that shelved their IPO plans in 2023 and 2024 are finally filing.
Analysts now project somewhere between 20 and 60 biotech IPOs for 2026, depending on who you ask and how optimistic they're feeling. That's not a return to the 2020-2021 frenzy, when practically anything with a pipeline could go public. Instead, it's a "bifurcated" market: investors are hungry for companies with real clinical data and clear paths forward, while platform-stage stories without human data face a much higher bar.
Scribe threaded that needle by combining a near-term clinical catalyst (first-in-human dosing for STX-1150), a differentiated technology platform, and strategic validation. Speaking of which: Sanofi bought 500,000 shares in a concurrent private placement at the IPO price, adding $7.5 million on top of the public raise. When a top-10 pharma company writes a check alongside public investors, it sends a message.
What Happens Next
The underwriters (Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo) also have a 30-day option to buy up to 1.287 million additional shares. If they exercise that greenshoe in full, Scribe's total haul could climb well past $140 million.
Before the IPO, Scribe had raised approximately $120 million in private funding across a $20 million Series A led by Andreessen Horowitz in 2018 and a $100 million Series B in 2021 led by Avoro Ventures, with participation from OrbiMed, RA Capital, Perceptive Advisors, T. Rowe Price, and others. The public offering roughly doubles the company's total capital raised.
The money will go toward pushing STX-1150 through clinical development. That first-in-human readout will be the real test. Preclinical data and a clever platform story got Scribe to the Nasdaq. Human data will determine whether it stays there.
The Bigger Picture
Scribe's IPO is a small but meaningful data point in a larger story: gene editing is graduating from a science project to a commercial reality. Casgevy (the CRISPR-based sickle cell therapy from CRISPR Therapeutics and Vertex) proved that gene editing can win FDA approval. Lilly's billion-dollar bet on Verve proved that big pharma believes in the cardiovascular application. And now Scribe has proven that public markets are willing to fund the next wave of contenders.
Two years ago, this deal wouldn't have happened. The fact that it priced at the top of the range, with pharma co-investment, tells you something about where sentiment stands. The gene-editing IPO window isn't just cracked open; for the right companies, it's inviting them in.
Deals & M&A
4 min read
Merck KGaA Just Dropped $11.3 Billion on a Company You've Probably Never Heard Of
Merck KGaA is spending $11.3 billion in cash to acquire Bio-Techne, a company most people outside the lab have never heard of. The deal is the largest life sciences tools acquisition of 2026 and a bold bet that owning the picks and shovels of drug discovery is just as valuable as the drugs themselves.
